Long-acting, multi-targeted nanomedicine: Addressing unmet medical need in acute lung injury

Journal of Biomedical Nanotechnology

Volumn 5, Issue 6, 2009, Pages 614-619

  Sadikot, Ruxana T ^a   Rubinstein, Israel ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

17 AAG; Drug delivery; GLP 1; Inflammation; Injury; Lung; Micelles; Nanobiotechnology; TREM 1

Indexed keywords

17-AAG; ACUTE LUNG INJURY; ACUTE RESPIRATORY DISTRESS SYNDROME; ALLYLAMINO; BASIC RESEARCH; CLINICAL USE; CRITICALLY-ILL PATIENTS; GLP-1; IN-VIVO; MEDICAL NEEDS; MYELOID CELLS; NANOMEDICINES; PATHOBIOLOGY; PEPTIDE DRUGS; REACTIVE OXYGEN SPECIES; SELF-ASSOCIATIONS;

AMIDES; ASSOCIATION REACTIONS; BIOCHEMISTRY; DRUG DELIVERY; INDUSTRIAL LABORATORIES; MEDICAL NANOTECHNOLOGY; MICELLES; MOLECULAR BIOLOGY; OXYGEN; PATHOLOGY; PEPTIDES; PHOSPHOLIPIDS;

BIOLOGICAL ORGANS;

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; HEAT SHOCK PROTEIN 90; MACROGOL 2000; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; TANESPIMYCIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ALPHA HELIX; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE MARROW CELL; CRITICALLY ILL PATIENT; DRUG DELIVERY SYSTEM; DRUG STABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICELLE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; REVIEW;

ACUTE LUNG INJURY; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; HUMANS; NANOCAPSULES; NANOMEDICINE;

EID: 76749156274     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1078     Document Type: Review

References (34)

1. M. Shey, E. J. Kongnyuy, J. Shang, and C. S. Wiysonge, A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS. Cochrane Database Syst. Rev. 8, CD005481 (2009).
2. B. Zahorowska, P. J. Crowe, and J. L. Yang, Combined therapies for cancer: A review of EGFR-targeted monotherapy and combination treatment with other drugs. J. Cancer Res. Clin. Oncol. 135, 1137 (2009).
3. O. M. Koo, I. Rubinstein, and H. Önyüksel, Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomedicine 1, 193 (2005).
4. T. D. Girard and G. B. Bernard, Mechanical ventilation in ARDS: A state-of-the-art review. Chest 131, 921 (2007).
5. M. A. Matthay and L. B. Ware, The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334 (2000).
6. M. A. Matthay, Treatment of acute lung injury: Clinical and experimental studies. Proc. Am. Thorac. Soc. 5, 297 (2008).
7. I. Rubinstein and H. Önyüksel, Biocompatible, biodegradable and sterically stabilized phospholipid nanomicelles improve cryopreservation of oral keratinocytes: A preliminary investigation. Int. J. Pharm. 338, 333 (2007).
8. R. T. Sadikot, P. S. Mohanty, M. Ornatowska, H. Onyuksel, and I. Rubinstein, Sterically stabilized phospholipid nanomicellar 17- allylaminodemethoxygeldanamycin inhibits lipopolysaccharide-induced activation of nuclear factor-κB in bone marrow-derived macrophages. Am. J. Respir. Crit. Care Med. 177, A75 (2008).
9. R. T. Sadikot, S. B. Lim, M. Ornatskowa, H. Onyuksel, and I. Rubinstein, TREM-1 self-associated with sterically stabilized phospholipid nanomicelles attenuates acute lung inflammation in mice. Am. J. Respir. Crit. Care Med. 177, A982 (2008).
10. R. T. Sadikot, S. Lim, X. Wang, J. W. Christman, H. Onyuksel, and I. Rubinstein, Salutary effects of nanomicellar GLP-1 administered after onset of LPS-induced acute lung inflammation in mice. Am. J. Respir. Crit. Care Med. 179, A5646 (2009).
11. G. D. Rubenfeld and M. S. Herridge, Epidemiology and outcomes of acute lung injury. Chest 131, 554 (2007).
12. C. S. Calfey and M. A. Matthay, Nonventilatory treatments for acute lung injury and ARDS. Chest 131, 913 (2007).
13. R. T. Sadikot, H. Zeng, M. Joo, M. B. Everhart, T. P. Sherrill, B. Li, D. S. Cheng, F. E. Yull, J. W. Christman, and T. S. Blackwell, Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J. Immunol. 176, 4923 (2006).
14. R. T. Sadikot, J. W. Christman, and T. S. Blackwell, Molecular targets for modulating lung inflammation and injury. Curr. Drug Targets 5, 581 (2004).
15. G. Matute-Bello, C. W. Frevert, and T. R. Martin, Animal models of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L379 (2008).
16. E. Lolis and R. Bucala, Therapeutic approaches to innate immunity: Severe sepsis and septic shock. Nat. Rev. Drug Discov. 2, 635 (2003).
17. J. Cohen, The immunopathogenesis of sepsis. Nature 420, 885 (2002).
18. R. T. Sadikot, E. D. Jansen, T. R. Blackwell, O. Zoia, F. Yull, J. W. Christman, and T. S. Blackwell, High-dose dexamethasone accentuates nuclear factor-kappa b activation in endotoxin-treated mice. Am. J. Respir. Crit. Care Med. 164, 873 (2001).
19. F. E. Yull, W. Han, E. D. Jansen, M. B. Everhart, R. T. Sadikot, J. W. Christman, and T. S. Blackwell, Bioluminescent detection of endotoxin effects on HIV-1 LTR-driven transcription in vivo. J. Histochem. Cytochem. 51, 741 (2003).
20. A. Bouchon, J. Dietrich, and M. Colonna, Cutting edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164, 4991 (2000).
21. M. Colonna, TREMs in the immune system and beyond. Nat. Rev. Immunol. 3, 1 (2003).
22. A. Bouchon, F. Facchetti, M. A. Weigand, and M. Colonna, TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410, 1103 (2001).
23. S. Gibot, P. E. le Renard, P. E. Bollaert, M. N. Kolopp-Sarda, M. C. Béné, G. C. Faure, and B. Lévy, Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med. 31, 594 (2005).
24. J. M. Cavaillon, Monocyte TREM-1 membrane expression in non-infectious inflammation. Crit. Care 13, 152 (2009).
25. M. G. Netea, T. Azam, G. Ferwerda, S. E. Girardin, S. H. Kim, and C. A. Dinarello, Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J. Leukoc. Biol. 80, 1454 (2006).
26. S. Gibot, C. Buonsanti, F. Massin, M. Romano, M. N. Kolopp-Sarda, F. Benigni, G. C. Faure, M. C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy, Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect. Immun. 74, 2823 (2006).
27. M. A. Nauck, Unrevaling the science off incretin biology. Am. J. Med. 122, S3 (2009).
28. S. Al-Sabah and D. Donnelly, The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. Protein Pept. Lett. 11, 9 (2004).
29. A. V. Fields, B. Patterson, A. A. Karnik, and R. P. Shannon, Glucagon-like peptide-1 and myocardial protection: More than glycemic control. Clin. Cardiol. 32, 236 (2009).
30. R. Abu-Hamdah, A. Rabiee, G. S. Meneilly, R. P. Shannon, D. K. Andersen, and D. Elahi, Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 94, 1843 (2009).
31. D. J. Stravopodis, L. H. Margaritis, and G. E. Voutsinas, Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr. Med. Chem. 14, 3122 (2007).
32. T. Taldone, A. Gozman, R. Maharaj, and G. Chiosis, Targeting Hsp90: Small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370 (2008).
33. V. Poulaki, E. Iliaki, N. Mitsiades, C. S. Mitsiades, Y. N. Paulus, D. V. Bula, E. S. Gragoudas, and J. W. Miller, Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 21, 2113 (2007).
34. A. Chatterjee, C. Dimitropoulou, F. Drakopanayiotakis, G. Antonova, C. Snead, J. Cannon, R. C. Venema, and J. D. Catravas, Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am. J. Respir. Crit. Care Med. 176, 667 (2007).